The EIT Health BRIDGEHEAD program aims to help health projects grow their businesses and validated products beyond the markets. BRIDGEHEAD is an internationalization program for European start-ups interested in being accompanied by one or more first-class accelerators from the EIT Health European network.

New companies travel to the accelerators of their choice to accelerate market access, take advantage of the local partner and customer networks, access infrastructure, and gain first-hand knowledge of the regulatory and commercial context.

Obtaining the CE mark as a medical device for our solution allows us to start selling immediately in the national market. At the same time, mjn-neuro is preparing to market its epilepsy device to the Dutch, German, and UK markets. Participation in the BRIDGEHEAD program is a great opportunity for mjn-neuro and will allow us to improve our knowledge of these markets and help us prepare a proper implementation strategy.

We are getting closer to achieving our goals

We would like to thank EIT Health for the confidence they have placed in mjn-neuro by granting us. We are getting closer to achieving our goals: helping people with epilepsy to have a better quality of life anywhere in Europe and in the future also in the United States.

Leave a Reply

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.